LONDON, January 19, 2012 /PRNewswire/ --
Bridge Bioresearch PLC (BBR) announced on the 20th of December 2011, that it has received approval for a phase 2a trial concerning Diabetic Foot Ulcer treatment with isoniazide.
The target molecule has patent protection for treatment based on Isoniazid embedded into a wound dressing and/or as a traditional tablet. Preliminary evidence has shown that isoniazide reduces the healing time of difficult to heal wounds such as pressure ulcers, chronic /venous ulcers and diabetic ulcers. Embedding Isoniazide directly into the dressing instead of applying it systematically could increase local therapeutic effect, reduce systemic side effects of the treatment and increase the ease of the use of the product. Currently no effective treatments exist for the chronic wounds.
Mary Anne Crandall in her report "World Wound Care Markets 2010" (June 2010) said many wounds do not heal at all and many lead to either amputation or death. Improving healing times and percentages of healed wounds would therefore greatly improve healthcare costs and patients' quality of life.
Moreover, Mr. Per Fischer from Fischer BioConsult ApS states: "That about 80% of the total cost of treating such wounds originates from nursing care, changing bandages, etc.; a significant reduction in healing times wound result in a very substantial reduction in health cost. In addition, the quality of life of the patients would also be greatly improved. It is therefore expected that a product with such characteristics would be in great demand."
In 2009, the total wound care market reached $14 billion USD, with annual growth rates running at 6.5%. It is projected that the market to reach some US$19 billion in 2014. The global distribution of market value in 2009 was US/CA 41%, EU 36%, JP 6%, and ROW 17%. In 2014 it is expected to be: US/CA 38%, EU 35%, JP 8%, and ROW 19%.
The present invention indicates much faster healing time, possibly up to a 50% reduction in healing time, resulting in 3 months of therapy on average for the new product, equivalent to approximately 34 dressing being used for patients at 2.5 dressing per week states Mr.Fischer.
About Bridge BioResearch
Bridge BioResearch PLC (BBR) is a drug development company with the corporate focus on Obesity, Type II Diabetes and related metabolic disorders as well as clinical stage testing. BBR continuously monitors databases for drug development and patents within the area. Targets are carefully selected for evaluation through proprietary assessment tools.
Enquiries should be directed to:
BRIDGE BIORESEARCH PLC
Kvæsthusgade 5C, 5th Floor DK-1251, Copenhagen K
2 Charterhouse Mews
London EC1M 6BB
SOURCE Bridge BioResearch Plc